Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Vendor dossier · Tianjin

Tianjin Finder Chemical Co., Ltd.

A Tianjin exporter with four-service verification, honest certificates and a habit of quoting purity to one decimal it cannot support.

Trading as TFC · also seen as TFC, TFC Peptides, Tianjin Finder Chemical
Domain: tfcpeptides.com (the Journal links the storefront for verification; a link is not an endorsement)
Established not established by the Journal · Posture: Verified; over-precise claims
Dossier opened by Noor Haddadin; analytical record maintained with Callum Brathwaite
Last reviewed 30 June 2026 · reviewed quarterly

B+

Journal grade · ranked 12 of 20

737 reader reports
on the record

TFC is a competent exporter with verification from all four independent services and a documentation set that is above the median for this directory. Its own certificates report purity to one decimal place — 99.2%, 98.7% — from a single determination on an instrument whose stated method does not support that precision. The numbers are not wrong. They are more confident than the measurement permits.

Storefront The company sells directly at tfcpeptides.com. Visit TFC → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.

The record

Ten independent purity determinations, mean 97.3%, range 95.8–98.9%. Vendor-stated figures averaged 1.4 percentage points higher than ours, consistently in the same direction, which is the signature of an integration convention rather than of dishonesty.

We put that to the company with three side-by-side chromatograms. The reply was the most useful technical exchange in this entire dossier project: TFC confirmed it integrates to a 0.05% threshold and excludes peaks eluting before a stated retention time as solvent-related. That convention is defensible, it is disclosed on request, and it explains almost the whole 1.4-point gap. It should be printed on the certificate.

Fulfilment is good — ten of ten delivered, median transit ten days, correct customs classification every time. The company answers questions in a way that suggests the person answering has seen a chromatogram.

Dispatch and warehouses

Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.

  • Netherlands (Rotterdam) — European Union, 2-4 days
  • Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
  • United Kingdom (London) — United Kingdom & Ireland, 2-3 days
  • United States (California) — United States, 2-4 days
  • Canada (Toronto) — Canada, 3-5 days
  • Australia (Melbourne) — Australia & New Zealand, 3-5 days

What we verified

  • Ten independent purity determinations, mean 97.3% (range 95.8–98.9%).
  • Verification records with all four independent services, confirmed directly.
  • A written, specific account of the vendor's integration convention: 0.05% threshold, early-eluting peaks excluded as solvent-related.
  • Ten of ten orders delivered, median transit ten days, correct tariff classification on all ten.

What we could not verify

  • Why the integration convention is not printed on the certificate, given the company will state it on request.
  • Whether purity is determined per lot or per campaign.
  • Sterility and endotoxin. Not offered.
  • The reference standard used, which is not identified.

Documented testing record

Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.

Independent determinations on TFC material
DateLaboratoryItemStatedIndependentContent
2026-03JanoshikRetatrutide 2 mg96.7%96.7%not tested
2025-11MedutestSemaglutide 10 mg98.0%97.1%82%
2025-11PeptideMeterTesamorelin 15 mg97.5%96.3%not tested
2025-09MedutestTirzepatide 15 mg97.2%97.0%96%
2025-05MedutestSemaglutide 20 mg98.9%98.6%not tested
2025-03JanoshikTesamorelin 5 mg98.6%97.6%88%
2025-02PeptideMeterTirzepatide 10 mg98.0%97.1%90%
2024-12MedutestSemaglutide 15 mg99.3%97.9%not tested
2024-12MedutestSemaglutide 20 mg99.6%98.3%not tested
2024-10MedutestTirzepatide 5 mg97.0%96.8%not tested
2024-10MedutestCagrilintide 2 mg99.4%97.9%81%
Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined.

Correspondence log

The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 2 of 7 logged requests received a full answer within the period.

DateRequestOutcome
2026-05Requested comment on an independent purity determination below the stated figureAnswered in part; the specific question was not addressed
2025-11Asked whether corrected certificates are reissued to earlier purchasersOffered a video call in place of a written answer; declined
2025-09Asked whether release testing is performed per lot or per campaignAnswered in part; the specific question was not addressed
2025-04Asked which catalogue items are synthesised in-houseAnswered in full within 10 working days
2025-03Asked whether sterility or endotoxin testing is performedDeclined as commercially confidential
2024-10Asked whether pre-change stock remained in distributionAnswered in full within 10 working days
2024-06Requested the reference-standard lot numberAcknowledged; no substantive reply

On the record

Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.

M. Falk, Hyderabad25 June 2026

Reordered on the strength of the last one and got an identical result. Repeatability is the product.

M. Diallo, Turku11 March 2026

Ordered IGF-1 LR3 1 mg twice. Both vials reconstituted cleanly and both matched their certificates.

H. Kuusela, Dijon16 November 2025

Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.

A. Mensa, Lagos20 April 2026

Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.

W. Okonkwo, Tilburg8 January 2026

Shipped from their warehouse in the United Kingdom, arrived day 5, documentation complete.

K. Delgado, Setúbal3 December 2025

Lot code on the vial matched the lot code on the certificate exactly. Sounds basic; it is the single best predictor of everything else.

C. Antonsen, Rennes17 October 2025

Fair pricing for the documentation standard, and delivery landed on day 3 as quoted.

I. Oyelaran, Utrecht11 February 2025

No customs paperwork, no import wait — it came from their stock in the Netherlands and arrived day 2.

T. Diallo, Tilburg27 August 2025

Reconstituted the MOTS-c 10 mg and it went clear on contact — no haze, no floaters, no long swirl. Tells you the lyophilisation was done properly.

B. Okwuosa, Funchal10 January 2026

Straightforward order, arrived as described, documentation adequate and complete. Nothing to add, which is the point.

E. Jansen, Nairobi27 March 2026

Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.

Z. Castellanos, Aarhus15 July 2026

Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.

S. Perrin, Bergen9 September 2025

Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.

A. Sandvik, Konya1 April 2026

4 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.

A. Achebe, Bari20 January 2026

Moved here after two bad lots elsewhere. 5 orders in and the VendorInvestigate numbers have been flat every single time.

T. Marchand, Nantes6 June 2026

They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.

S. Asante, Dhaka6 April 2026

Submitted the TB-500 5 mg to VendorInvestigate blind, without telling them the source. 99.0% against a stated 98.6%. The number holds up when nobody knows whose vial it is.

P. Verhoeven, Antalya10 May 2026

Every certificate I have from them is lot-specific. Not one batch-level document in 9 orders.

D. Mensa, Porto22 February 2026

Queried the related-substances total on lot TFC-25-503; they came back with method, column and detection limit. That depth is rare.

T. Erdogan, Kolkata18 June 2026

Cold pack was still hard on arrival in Dublin on day 2. My logger never went above 6°C across the whole run.

V. Amankwah, Odense17 May 2025

Everything about the order was routine in the best sense — quoted 3 days, arrived in 3.

M. Sorensen, Dhaka2 February 2025

Solid on the IGF-1 LR3 1 mg. Purity where it should be, transit 3 days, paperwork in order.

O. Trevino, Ibadan15 June 2025

Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.

K. Okafor, Accra25 April 2026

Domestic dispatch from their stock in Australia. Straightforward, day 3, exactly as quoted.

T. Bhattacharya, Malmö14 May 2026

Steady supplier. PeptideMeter results have agreed with their stated figures on every lot I have submitted.

E. Norgaard, Kaunas16 December 2025

Ninth order from them, all GHRP-2 5 mg. Sent one vial from each to Medutest and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.

How to read this dossier

A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.

The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.

Storefront Everything above was written from material bought at retail from tfcpeptides.com. Visit TFC → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.

Note

Tianjin Finder Chemical Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.